Getting your player ready...
Stock of Allos Therapeutics Inc., a cancer drugmaker that received a takeover offer from AMAG Pharmaceuticals Inc., dropped to a record low after saying a second bid by a rival company was withdrawn.
Allos, based in Westminster, fell 18 percent to $1.43 Monday, after touching $1.38, the lowest price since the stock began trading in March 2000. The shares have fallen 62 percent in the past year before Monday.
Allos is working with AMAG to complete the all-stock acquisition, the company said in a statement Monday.
